Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study

Erin F Barreto, Andrew D Rule, Mohammad H Alshaer, Jason A Roberts, Mohd Hafiz Abdul Aziz, Marc H Scheetz, Kristin C Mara, Paul J Jannetto, Ognjen Gajic, John C O'Horo, Kasey R Boehmer, Erin F Barreto, Andrew D Rule, Mohammad H Alshaer, Jason A Roberts, Mohd Hafiz Abdul Aziz, Marc H Scheetz, Kristin C Mara, Paul J Jannetto, Ognjen Gajic, John C O'Horo, Kasey R Boehmer

Abstract

Background: Beta-lactams (i.e., penicillins, cephalosporins, carbapenems, monobactams) are the most widely used class of antibiotics in critically ill patients. There is substantial interpatient variability in beta-lactam pharmacokinetics which renders their effectiveness and safety largely unpredictable. One strategy to ensure achievement of therapeutic concentrations is drug level testing ("therapeutic drug monitoring"; TDM). While studies have suggested promise with beta-lactam TDM, it is not yet widely available or implemented. This protocol presents a mixed-methods study designed to examine healthcare practitioners' perspectives on the use and implementation of beta-lactam TDM in the critically ill.

Methods: An explanatory sequential mixed-methods design will be used [QUANT → qual]. First, quantitative data will be collected through a web-based questionnaire directed at clinicians at three academic medical centers at different phases of beta-lactam TDM implementation (not yet implemented, partially implemented, fully implemented). The sampling frame will include providers from a variety of disciplines that interact with drug level testing and interpretation in the critical care environment including pharmacists, intensivists, infectious diseases experts, medical/surgical trainees, and advanced practice providers. Second, approximately 30 individuals will be purposively sampled from survey respondents to conduct in-depth qualitative interviews to explain and expand upon the results from the quantitative strand. Normalization Process Theory and the Consolidated Framework for Implementation Science will be used to guide data analysis.

Discussion: These data will be used to answer two specific questions: "What are ICU practitioners' perspectives on implementing beta-lactam TDM?" and "What factors contribute to the success of beta-lactam TDM program implementation?" Results of this study will be used to design future implementation strategies for beta-lactam TDM programs in the critically ill.

Trial registration: NCT04755777 .

Keywords: Beta-lactams; Implementation; Intensive care unit; Mixed-methods; Pharmacokinetics/pharmacodynamics; Study protocol; Therapeutic drug monitoring.

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Study schema

References

    1. Liu VX, Fielding-Singh V, Greene JD, Baker JM, Iwashyna TJ, Bhattacharya J, Escobar GJ. The timing of early antibiotics and hospital mortality in sepsis. Am J Respir Crit Care Med. 2017;196(7):856–863. doi: 10.1164/rccm.201609-1848OC.
    1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, de Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552. doi: 10.1097/CCM.0000000000002255.
    1. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–111. Available from: .
    1. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJCC, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133–164. doi: 10.1086/649554.
    1. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147–159. doi: 10.1093/cid/ciu444.
    1. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267–1284. doi: 10.1086/425368.
    1. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: Defining antibiotic levels in intensive care unit patients: are current ß-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072–1083. doi: 10.1093/cid/ciu027.
    1. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14(4):R126. doi: 10.1186/cc9091.
    1. Carlier M, Carrette S, Stove V, Verstraete AG, De Waele JJ. Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course. Int J Antimicrob Agents. 2014;43:470–473. doi: 10.1016/j.ijantimicag.2014.01.028.
    1. Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care. 2011;15:R206. doi: 10.1186/cc10441.
    1. Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127–1153. doi: 10.1007/s00134-020-06050-1.
    1. Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients - guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique - SFPT) and the French Society of Anaesthesia. Crit Care. 2019;23:1–20. doi: 10.1186/s13054-019-2378-9.
    1. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988;158(4):831–847. doi: 10.1093/infdis/158.4.831.
    1. Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017;21:1–8. doi: 10.1186/s13054-017-1856-1.
    1. Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011;72(3):381–393. doi: 10.1111/j.1365-2125.2011.03991.x.
    1. Sugimoto M, Uchida I, Mashimo T, Yamazaki S, Hatano K, Ikeda F, Mochizuki Y, Terai T, Matsuoka N. Evidence for the involvement of GABA A receptor blockade in convulsions induced by cephalosporins. Neuropharmacology. 2003;45(3):304–314. doi: 10.1016/S0028-3908(03)00188-6.
    1. Cies JJ, Moore WS, Enache A, Chopra A. β-lactam therapeutic drug management in the PICU. Crit Care Med. 2018;46:272–279. doi: 10.1097/CCM.0000000000002817.
    1. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, et al. Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36:332–339. doi: 10.1016/j.ijantimicag.2010.06.008.
    1. Patel BM, Paratz J, See NC, Muller MJ, Rudd M, Paterson D, Briscoe SE, Ungerer J, McWhinney BC, Lipman J, Roberts JA. Therapeutic drug monitoring of beta-lactam antibiotics in burns patients-a one-year prospective study. Ther Drug Monit. 2012;34(2):160–164. doi: 10.1097/FTD.0b013e31824981a6.
    1. Fournier A, Eggimann P, Pantet O, Pagani JL, Dupuis-lozeron E, Pannatier A, et al. Impact of real-time therapeutic drug monitoring on the prescription of antibiotics in burn patients requiring admission to the intensive care unit. Antimicrob Agents Chemother. 2017;62:AAC.01818-17. doi: 10.1128/AAC.01818-17.
    1. Tabah A, de Waele J, Lipman J, Zahar JR, Cotta MO, Barton G, Timsit JF, Roberts JA. The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother. 2015;70(9):2671–2677. doi: 10.1093/jac/dkv165.
    1. Liebchen U, Paal M, Scharf C, Schroeder I, Grabein B, Zander J, et al. The ONTAI study – a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units. J Crit Care. 2020;60:260–266. doi: 10.1016/j.jcrc.2020.08.027.
    1. Nicolau D, Belliveau P, Nightingale C, Quintiliani R, Freeman C. Implementation of a once-daily aminoglycoside program in a large community-teaching hospital. Hosp Pharm. 1995;30:674–680.
    1. Gregory ER, Burgess DR, Cotner SE, VanHoose JD, Flannery AH, Gardner B, et al. Pharmacist survey: pharmacist perception of vancomycin area under the curve therapeutic drug monitoring. J Pharm Pract. 2019:089719001986749. 10.1177/0897190019867494.
    1. Gregory ER, Burgess DR, Cotner SE, VanHoose JD, Flannery AH, Gardner B, et al. Vancomycin area under the curve dosing and monitoring at an academic medical center: transition strategies and lessons learned. J Pharm Pract. 2020;33(6):774–8.
    1. Kufel WD, Seabury RW, Mogle BT, Beccari MV, Probst LA, Steele JM. Readiness to implement vancomycin monitoring based on area under the concentration-time curve: a cross-sectional survey of a national health consortium. Am J Heal Pharm. 2019;76(12):889–894. doi: 10.1093/ajhp/zxz070.
    1. Kelley K, Clark B, Brown V, Sitzia J. Good practice in the conduct and reporting of survey research. Int J Qual Heal Care. 2003;15(3):261–266. doi: 10.1093/intqhc/mzg031.
    1. Bennett C, Khangura S, Brehaut JC, Graham ID, Moher D, Potter BK, et al. Reporting guidelines for survey research: an analysis of published guidance and reporting practices. Jewkes R, editor. PLoS Med. 2011;8:e1001069. doi: 10.1371/journal.pmed.1001069.
    1. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Heal Care. 2007;19:349–357. doi: 10.1093/intqhc/mzm042.
    1. Creswell J, Plano CV. Designing and conducting mixed methods research. 3rd Revise. Thousand Oaks: SAGE Publications Inc; 2017.
    1. Frazee E, Rule AD, Lieske JC, Kashani KB, Barreto JN, Virk A, et al. Cystatin C-guided vancomycin dosing in critically ill patients: a quality improvement project. Am J Kidney Dis. 2017;69:658–666. doi: 10.1053/j.ajkd.2016.11.016.
    1. Barreto EF, Rule AD, Voils SA, Kane-Gill SL. Innovative use of novel biomarkers to improve the safety of renally eliminated and nephrotoxic medications. Pharmacotherapy. 2018;38:794–803. doi: 10.1002/phar.2149.
    1. Weaver L, Beebe TJ, Rockwood T. The impact of survey mode on the response rate in a survey of the factors that influence Minnesota physicians’ disclosure practices. BMC Med Res Methodol. 2019;19:1–7. doi: 10.1186/s12874-019-0719-7.
    1. Frazee EN, Personett HA, Bauer SR, Dzierba AL, Stollings JL, Ryder LP, Elmer JL, Caples SM, Daniels CE. Intensive care nurses’ knowledge about use of neuromuscular blocking agents in patients with respiratory failure. Am J Crit Care. 2015;24(5):431–439. doi: 10.4037/ajcc2015397.
    1. Torbic H, Bauer SRSR, Personett HA, Dzierba ALAL, Stollings JLJL, Ryder LPLP, et al. Perceived safety and efficacy of neuromuscular blockers for acute respiratory distress syndrome among medical intensive care unit practitioners: a multicenter survey. J Crit Care. 2017;38:278–283. doi: 10.1016/j.jcrc.2016.11.040.
    1. Leppin AL, Schaepe K, Egginton J, Dick S, Branda M, Christiansen L, et al. Integrating community-based health promotion programs and primary care: a mixed methods analysis of feasibility. BMC Health Serv Res. 2018;18:72. doi: 10.1186/s12913-018-2866-7.
    1. May C, Finch T. Implementing, embedding, and integrating practices: an outline of normalization process theory. Sociology. 2009;43(3):535–554. doi: 10.1177/0038038509103208.
    1. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. doi: 10.1186/1748-5908-4-50.
    1. Steffen K, Doctor A, Hoerr J, Gill J, Markham C, Brown SM, Cohen D, Hansen R, Kryzer E, Richards J, Small S, Valentine S, York JL, Proctor EK, Spinella PC. Controlling phlebotomy volume diminishes PICU transfusion: implementation processes and impact. Pediatrics. 2017;140(2):e20162480. doi: 10.1542/peds.2016-2480.
    1. Kahn JM. Disseminating clinical trial results in critical care. Crit Care Med. 2009;37(Supplement):S147–S153. doi: 10.1097/CCM.0b013e3181920fa3.
    1. Charani E, Ahmad R, Tarrant C, Birgand G, Leather A, Mendelson M, Moonesinghe SR, Sevdalis N, Singh S, Holmes A. Opportunities for system level improvement in antibiotic use across the surgical pathway. Int J Infect Dis. 2017;60:29–34. doi: 10.1016/j.ijid.2017.04.020.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir